Skip Navigation LinksHome > Professional Development > AABB US Hemovigilance Symposium

AABB US Hemovigilance Symposium

​Feb 13-14, 2017

Event Description

AABB US Hemovigilance Symposium is the first of what is intended to become an annual event to bring together experts from the United States and around the world to discuss progress in US hemovigilance. Experts will address the state of US hemovigilance, recognizing the successes of the past 10 years, identify challenges such as perceived barriers to participation, and share recommendations for future improvement and harmonization.

Learning Objectives

  1. Describe the current process for reporting adverse transfusion related events in the US.
  2. Discuss international hemovigilance programs and how they differ from those in the US.
  3. Review current infectious risks associated with blood safety and the latest surveillance programs addressing these risks.
  4. Describe approaches to donor health and safety through hemovigilance and blood center driven safety activities.
  5. Learn about the challenges to hemovigilance in the US, including event reporting strategies used by different types of hospitals.
  6. Describe existing and perceived barriers to participation in hemovigilance programs and approaches for increasing participation.

Agenda

Day 1

1:00 pm Meeting Opening
AABB Hemovigilance Committee Chair: Mark Fung, MD, PhD (UVM)
  Value, Purpose and Vision of Hemovigilance: Where We’ve Been and Where We Can Be Going
Keynote speaker: Harvey Klein, MD (NIH)
1:45 pm Hemovigilance Throughout the Globe
  • Paula Bolton-Maggs, DM, FRCP, FRCPath (United Kingdom)
  • Nancy Heddle, MSc, FCSMLS(D) (Canada)
  • Philippe Renaudier (France)

This session will include descriptions of the Hemovigilance Systems in the United Kingdom, Canada and France.  Speakers will focus on a few major insights or process changes that have successfully impacted transfusion practice &/or patient care that have resulted from their Hemovigilance System’s findings.

3:00 pm Break
3:30 pm State of US Hemovigilance: Taking Stock of Accomplishments
Moderator: Michael Murphy, MD, FRCP, FRCPath, FFPath
  • Kathryn Haass, MPH, CPH, MT(AAB), BB(ASCP)CMM (CDC)
  • Steven Anderson, PhD, MPP (FDA)
  • Melissa Cumming, MS (Massachusetts Department of Public Health)
  • Ross Herron, MD (American Red Cross)
  • Barbee Whitaker, PhD (AABB Center for Patient Safety)

This session will include discussions of US Hemovigilance from five different perspectives; the US Food & Drug Administration, the US Centers for Disease Control & Prevention, the State of Massachusetts, the American Red Cross & the AABB Center for Patient Safety (Patient Safety Organization).  Each speaker will describe their organization’s contributions to hemovigilance in the United States, including findings & recommendations that may have an impact on transfusion patient safety.

5:30 pm Panel Discussion
This panel will address the afternoon speaker’s visions for the future of hemovigilance in the US, recommendations for how to most effectively use the systems, & how to turn surveillance into practical improvements for patient care & transfusion practice.
6:00 pm Adjourn

Day 2

8:30 am Hemovigilance Relating to Donors and Starting Material
Moderator: Steven Anderson, PhD, MPP (FDA)  
  Donor Hemovigilance: Blood Collectors Pioneering the Way
Donor Vigilance, DonorHART and Gaps in Donor Health and Safety
James Stubbs, MD (Mayo Clinic)
  Infectious Risks
  • REDS-III Hemovigilance – Brian Custer, PhD, MPH (Blood Systems)
  • Transfusion-Transmissible Infections Monitoring System (TTIMS) Steering Committee
    • Brian Custer, PhD, MPH
    • Susan Stramer, PhD
  • Hemovigilance and Impact of Pathogen Reduction - Laurence Corash. MD (Cerus)

This session will address donor hemovigilance & patient safety through interventions that are realized through blood center screenings.  Several national programs will be described including the AABB Donor Hemovigilance Program using the Donor Hemovigilance Analysis & reporting Tool (Donor-HARTTM), the Recipient Epidemiology & Donor Evaluation Study-III (REDS-III), & the Transfusion-Transmissible Infections Monitoring Systems (TTIMS) program.  This session will discuss program contributions to donor & patient safety.  Hemovigilance through post marketing surveillance of new innovation, specifically pathogen reduction, will be discussed.

10:30 am Challenges to US Hemovigilance I: Approaches to Data Validation and Verification
Moderator: James P. AuBuchon, MD, FCAP, FRCP (Edin)
  • Nancy Heddle, MSc, FCSMLS(D) (McMaster University)  
  • Paula Bolton-Maggs, DM, FRCP, FRCPath (UK SHOT)
  • Philippe Renaudier (France)
  • Barbee Whitaker, PhD (AABB CPS)
  • Panel Discussion Q&A

This session will begin with a description of how each national program handles validation & verification of cases, how the systems assure reporting accuracy, completeness both within & among hospitals, & how participation is defined & documented among reporting hospitals.  This discussion will include a description of how mistakes, errors or incidents that impact patient safety are included in each hemovigilance system. 

11:30 am Practical Hemovigilance: Local Approaches and Challenges to Managing Hemovigilance
Moderator: Yanyun Wu, MD 
  • James Stubbs, MD (Mayo)
  • Pampee Young, MD, PhD (Vanderbilt)

This session will focus on what hospitals must do to manage hemovigilance data collection, event categorization, & reporting.  The unique challenges experienced by large, small & pediatric hospitals will be addressed.

12:30 - 1:15 pm LUNCH
1:15 pm Challenges to US Hemovigilance II: Existing and Perceived Barriers to Participation
Moderator: Barbee Whitaker, PhD
  • Pampee Young, MD, PhD (Hospital perspective)
  • Misha Baker, MPH (CDC)
  • Mark Fung, MD, PhD (Private sector perspective)
  • Paula Bolton-Maggs, DM, FRCP, FRCPath (International perspective)
  • Panel Discussion Q&A

Panel Discussion Q&A
In this session, speakers will outline barriers to participation in the US hemovigilance system & those experienced by the other countries as they develop hemovigilance programs.  Each speaker will make recommendations for how these might be mitigated & what might be accomplished in the future through hemovigilance programs.

2:45 pm Concluding Statements and Open Comments from Audience
AABB Hemovigilance Committee Chair: Mark Fung, MD, PhD
3:00 pm Adjourn

Event Level

Intermediate

Continuing Education Information

The AABB is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians

AABB is an approved, and accredited provider (Provider Number 0000381) by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AABB designates these educational activities for a maximum of 9.75 credit hours in Category 1 credits toward the AMA Physicians Recognition AwardTM. Each physician should claim only those credits that he/she actually spent in the activity.

Florida Clinical Laboratory Personnel*

AABB is approved by the Florida Board of Clinical Laboratory Personnel, Provider Number 50-4261-1, as a provider of continuing education programs for Florida-licensed clinical laboratory personnel. This event has been approved for a maximum of 11.75 contact hours.

California Clinical Laboratory Personnel*

AABB is an approved accrediting agency for continuing education for California licensed clinical laboratory personnel. This event has been approved for a maximum of 11.75 contact hours. AABB’s accrediting agency number is 0011. Credit earned through attendance at this event may be used to fulfill the state requirement for continuing education hours to maintain licensure status.

*Please note that PACE credits are provided through Florida and California Labs.

California Nurses

AABB is approved by the California Board of Registered Nursing, Provider Number 4341, as a provider of continuing nursing education programs. AABB designates this event for a maximum of 9.75 contact hours.

ASCP-Certified Professionals

All AABB educational programs are ACCME accredited and satisfy the “formal education” option of the American Society of Clinical Pathologists (ASCP) Certification Maintenance Program (CMP).

General Attendees

Administrators, laboratory personnel, nurses (non-California) and general attendees may receive a certificate of attendance for participation in this event. This certificate verifies attendance at the conference.

Registration Fees

Due to a generous educational grant from Cerus, this event is free for all attendees registering through January 31, 2017. 

Starting February 1, 2017, registration will be $100.

Location

Loews Atlanta Hotel
1065 Peachtree St, NE
Atlanta, GA 30309

Book by phone +1.888.563.9736.
Please mention AABB Hemovigilance Symposium when booking by phone.

Rate: $219.00/night

This event room rate expired on January 26, 2017. AABB can no longer guarantee the event room rate.

If you need to book a room for Sunday, February 12, 2017, please contact the hotel directly at +1.888.563.9736.

Audience

Physicians, Scientists, Technologists, Nurses, Managers/Supervisors

Supported by Cerus.